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Abstract
The Epstein-Barr virus (EBV) nuclear proteins EBNA3A, EBNA3B, and EBNA3C interact
with the cell DNA binding protein RBPJ and regulate cell and viral genes. Repression of the
CDKN2A tumor suppressor gene products p16INK4A and p14ARF by EBNA3A and EBNA3C
is critical for EBV mediated transformation of resting B lymphocytes into immortalized lym-
phoblastoid cell lines (LCLs). To define the composition of endogenous EBNA3 protein
complexes, we generated lymphoblastoid cell lines (LCLs) expressing flag-HA tagged
EBNA3A, EBNA3B, or EBNA3C and used tandem affinity purification to isolate each
EBNA3 complex. Our results demonstrated that each EBNA3 protein forms a distinct com-
plex with RBPJ. Mass-spectrometry revealed that the EBNA3A and EBNA3B complexes
also contained the deubquitylation complex consisting of WDR48, WDR20, and USP46
(or its paralog USP12) and that EBNA3C complexes contained WDR48. Immunoprecipita-
tion confirmed that EBNA3A, EBNA3B, and EBNA3C association with the USP46 complex.
Using chromatin immunoprecipitation, we demonstrate that WDR48 and USP46 are re-
cruited to the p14ARF promoter in an EBNA3C dependent manner. Mapping studies were
consistent with WDR48 being the primary mediator of EBNA3 association with the DUB
complex. By ChIP assay, WDR48 was recruited to the p14ARF promoter in an EBNA3C de-
pendent manner. Importantly, WDR48 associated with EBNA3A and EBNA3C domains
that are critical for LCL growth, suggesting a role for USP46/USP12 in EBV induced
growth transformation.
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Author Summary
Epstein-Barr virus (EBV) is a gammaherpesvirus implicated in the pathogenesis of multiple
malignancies, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lympho-
proliferative disease (PTLD), nasopharyngeal carcinoma, and gastric carcinoma. EBV infec-
tion of resting B-lymphocytes drives them to proliferate as lymphoblastoid cell lines (LCLs),
an in vitro model of PTLD. LCLs express a limited EBV gene repertoire, including six nucle-
ar proteins (EBNA1, 2, 3A, 3B, 3C, and LP), three integral membrane proteins (LMP1, 2A,
and 2B), and more than 30 micro RNAs. EBNA2 and the EBNA3 proteins are transcription
factors that regulate viral and cell gene expression through the cell DNA binding protein
RBPJ. In this study, we established LCLs transformed by recombinant EBV genomes in
which a Flag-HA epitope tag is fused in-frame to the C-terminus of EBNA3A, EBNA3B or
EBNA3C. Using these LCLs, we purified endogenous EBNA3 complexes and identified the
USP46 deubiquitinating enzyme (DUB) and its associated chaperones WDR48 andWDR20
as EBNA3 binding proteins. We find that EBNA3s interact primarily with the WDR48 pro-
tein and that loss of WDR48 interaction with EBNA3A or EBNA3C impairs LCL growth.
This study represents the first characterization of EBNA3 complexes from LCLs and impli-
cates the USP46 DUB complex in EBNA3 mediated gene regulation.
Introduction
Epstein-Barr Virus (EBV) is a herpesvirus that establishes lifelong asymptomatic infection in
up to 95% of the human population [1]. In vitro, EBV infection of resting B lymphocytes drives
them to proliferate as lymphoblastoid cell lines (LCLs) [2,3]. The EBV genome resides in LCLs
as a non-integrated episome and expresses a limited gene repertoire called latency III, which in-
cludes genes encoding six nuclear proteins (EBNA1, 2, 3A, 3B, 3C, and LP), three integral
membrane proteins (LMP1, 2A, and 2B), and more than 30 micro RNAs (miRs) [1]. Latency
III driven B lymphocyte proliferation in vivo is normally controlled by a vigorous cytotoxic T
cell response [4]. In the absence of an effective immune response or in collaboration with vari-
ous environmental or genetic co-factors, EBV latent infection can result in malignancies, in-
cluding Burkitt and Hodgkin lymphomas, post-transplant lymphoproliferative disease
(PTLD), as well as nasopharyngeal and gastric carcinomas [1].
Extensive genetic and biochemical data support the model that EBV latency III gene expres-
sion usurps growth and survival signaling pathways in B lymphocytes normally triggered by
antigen recognition and CD4+ T cell co-stimulation [1,5]. LMP1 expression results in constitu-
tive NF-kB activation that is essential for LCL outgrowth and survival. The ability of LMP1 to
self-associate allows it to activate, in a ligand independent manner, molecules that transduce
signals from receptors in the TNF superfamily [6,7,8,9,10]. The other two latent membrane
proteins, LMP2A and LMP2B, are not required for LCL transformation in vitro [11]. The abili-
ty of LMP2A to engage B cell receptor signaling molecules may be important for maintaining
viral latency or for the growth and survival of EBV infected cells in vivo [12,13]. EBNA2 is an
acidic transactivator that is targeted to promoters through an interaction with the RBPJ DNA
binding protein, a component of the Notch signaling pathway [14]. EBNA2 and its co-activator
EBNALP are the first genes expressed during EBV latent infection and result in upregulation of
promoters including c-myc, EBV LMP1, LMP2A, and EBNA essential for latency III transfor-
mation [15,16]. Global analysis of EBNA2 and RBPJ binding in LCLs has implicated EBF1 and
other B cell transcription factors as pioneering factors for EBNA2 binding of promoters and
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enhancers [17]. In contrast, the role of the EBNA3 proteins in LCL transformation is less
clearly defined.
The EBNA3 protein family is defined by a ~300 aa region of homology in their N-termini;
there are no known homologs outside of EBV and the closely related primate lymphocrypto-
viruses. EBNA3A, EBNA3B, and EBNA3C share a common exon structure consisting of a short
5’ exon and a longer 3’ exon arranged in a tandem array that likely arose from triplication of a
single ancestral EBNA3 gene [1]. Reverse genetic analyses have demonstrated that EBNA3C is
essential for LCL transformation, while EBNA3B is dispensable [18,19]. The requirement for
EBNA3A is probably intermediate. EBNA3A truncation or conditional inactivation abrogated
transformation in multiple studies. However, LCLs have been generated under appropriate con-
ditions, using feeder cells, with an EBV genome deleted for EBNA3A [20]. The most convincing
evidence of the unique requirement for EBNA3A and EBNA3C derives from LCLs in which ei-
ther EBNA3A or EBNA3C has been rendered conditional by fusion to a mutant estrogen hor-
mone binding domain [21,22,23,24,25]. In this system, LCL growth arrest induced by EBNA3A
inactivation could be rescued only by exogenous EBNA3A expression, but not by expression of
additional EBNA3B or EBNA3C [22,23]. Similarly, EBNA3C inactivation results in termination
of LCL growth that can only be restored by EBNA3C [21,24,25].
Cell cycle effects of the EBNA3 proteins, particularly EBNA3C, have been documented in
many other systems. EBNA3C can overcome serum deprivation and disrupt the G1 checkpoint
in REFs, NIH3T3, and U2OS cells [26]. Additionally EBNA3C overexpression can disrupt mi-
totic spindle checkpoints and produce aneuploidy [26,27]. EBNA3A and EBNA3C can cooper-
ate with HRAS in classical transformation assays [28]. Multiple mechanisms of EBNA3C
mediated effects have been suggested, including inhibition of accumulation of the CDK inhibi-
tors p27KIP1 and p16INK4A, Rb degradation via the SCF ubiquitin ligase, c-myc stabilization,
and binding to, and inactivation of cyclinA-CDK complexes [29,30,31]. In LCLs, the growth ef-
fects of EBNA3A and EBNA3C appear to be primarily due to suppression of the CDKN2A
gene products p16INK4A and p14ARF [32]. Conditional inactivation of either EBNA3A or
EBNA3C results in p16INK4A and p14ARF accumulation and cessation of growth. Moreover,
siRNA knockdown of both gene products restores growth despite EBNA3A or EBNA3C inacti-
vation. EBNA3A and EBNA3C effects appear to be at the level of CDKN2A transcription as
changes in protein levels are accompanied by concomitant increases in mRNA and a substan-
tial reduction of the repressive H3K27me3 modification at the CDKN2A promoter [32]. Fur-
thermore, p16INK4A null B lymphocytes can be transformed into LCLs in the absence of
functional EBNA3C protein [33].
Although the mechanism by which EBNA3A and EBNA3C cooperatively suppress CDKN2A
is unknown, gene co-regulation by the EBNA3 proteins appears to be frequent. In LCLs, 52 out
of 287 genes reported as EBNA3A regulated were found to also be regulated by EBNA3C [34]. In
Burkitt lymphoma cells, EBNA3A and EBNA3C are both required for suppression of BIM, a
pro-apoptotic Bcl-2 family member [35]. Genome-wide analysis of EBNA3A, EBNA3B, and
EBNA3C effects in BL31 cells infected with recombinant EBV genomes [36], suggested that
about half of the cell genes differentially expressed as a result of deletion of one EBNA3 ORF are
similarly affected by deletion of at least one of the other EBNA3s. In that study, overlap among
genes regulated by EBNA3B and EBNA3C was particularly extensive [36].
A large number of interacting proteins have been suggested to be important for EBNA3 ac-
tivities. Of these, RBPJ is the best established as a mediator of transcriptional and LCL growth
promoting effects [37,38,39,40]. RBPJ is bound by the conserved N-terminal EBNA3 domain,
which unlike Notch and EBNA2, does not interact with the RBPJ’s beta-trefoil domain. In-
stead, the EBNA3s bind to the N-terminal rel-homology domain (NTD) of RBPJ [37,41]. Al-
though biochemical assays suggested that the EBNA3-NTD interaction could inhibit RBPJ
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DNA binding, genome-wide co-localization between EBNA3 proteins and RBPJ has been dem-
onstrated by ChIP-seq [42,43]. Genetic analyses have demonstrated that interaction of both
EBNA3A and EBNA3C with RBPJ is essential for CDKN2A promoter repression and mainte-
nance of LCL growth [32,33]. A second cell protein important for CDKN2A regulation is
CtBP1, which interacts with the C-terminal regions of EBNA3A and EBNA3C [44,45,46]. Mu-
tation of the CtBP1 binding sites in EBNA3A and EBNA3C impairs their ability to support
LCL growth. By contrast, RBPJ binding mutants are completely defective in maintenance of
LCL growth [21,24].
The strength of evidence supporting a role for other interacting proteins in mediating EBNA3
growth effects varies considerably. Although significant progress has been made in mapping the
EBNA3 domains critical for LCL growth, for most interacting proteins, mutations within the
EBNA3 proteins that selectively disrupt their binding have yet to be identified. In parallel with ef-
forts to correlate ongoing genetic analysis of the EBNA3 proteins with interacting protein bind-
ing, we set out to devise a means of purifying endogenous EBNA3 complexes from LCLs and to
determine their protein constituents. To that end, recombinant EBV genomes in which DNA en-
coding a flag-HA (F-HA) epitope is inserted in-frame to the C-terminus of the EBNA3A,
EBNA3B, or EBNA3C ORF were constructed. These genomes were used to transform primary
B-lymphocytes into three cell lines: EBNA3A-F-HA, EBNA3B-F-HA, and EBNA3C-F-HA
LCLs. Using tandem affinity purification and LC/MS/MS, we characterized the protein composi-
tion of endogenous EBNA3A, EBNA3B, and EBNA3C complexes in these LCLs.
Here we show that each EBNA3 protein is associated with the USP46 and USP12 deubiqui-
tylase (DUB) complexes, and that the domains of the EBNA3A and EBNA3C proteins that
bind these DUBs are important for maintenance of LCL growth. In the presence of EBNA3
proteins, RBPJ and the USP46/USP12 enzymes become associated and, when purified, these
EBNA3 containing complexes exhibit DUB activity. Using CRIPSR/Cas9 we provide evidence
that USP46 is essential in 721 LCLs, but dispensable in 293T cells. Further, using chromatin
immunoprecipitation we demonstrate increased binding of WDR48 to the p14ARF promoter in
the presence of functional EBNA3C protein. We propose a model in which EBNA3s serve as
adaptor proteins between USP46/USP12 and RBPJ, recruiting these DUB complexes to chro-
matin to regulate transcription.
Results
Production and characterization of LCLs expressing epitope tagged
EBNA3 proteins
In order to study endogenous EBNA3 complexes from LCLs, we generated recombinant EBV
genomes in which flag and HA epitope tags are fused in-frame with the carboxyl-terminus of
EBNA3A, EBNA3B, or EBNA3C, using a previously described EBV BACmid [47]. These re-
combinant EBV genomes were used to transform B lymphocytes into LCLs, designated
EBNA3A-F-HA LCL, EBNA3B-F-HA LCL, and EBNA3C-F-HA LCL, respectively, and collec-
tively referred to as the EBNA3-F-HA LCLs. Additionally, a control a wild-type LCL was created
using the unmodified EBV BACmid as the transforming genome. Western blotting of the three
EBNA3-F-HA and wild-type LCLs revealed that RBPJ, EBNA1, EBNA2, EBNALP, and LMP1
levels in whole cell extracts were indistinguishable among the different cell lines (S1 Fig). The
epitope tagged EBNA3 proteins were expressed at levels comparable to their wild-type counter-
parts and, as expected, migrated as slightly higher apparent molecular weights than the untagged
proteins. Interestingly, the EBNA3B-F-HA LCL was hypomorphic for EBNA3C expression and
exhibited a slower rate of growth than the other LCLs. A similar reduction in EBNA3C expres-
sion and rate of growth was previously reported in an LCL in which the EBNA3B gene was
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replaced by a chloramphenicol cassette [48]. Thus, the fusion of flag-HA tags to each of the
EBNA3 open reading frames resulted in transformation competent EBVs that express latency
proteins at levels comparable to those seen in wild-type LCLs.
EBNA3 proteins exist in distinct complexes within LCLs
RBPJ immunoprecipitation efficiently retrieves four of the six EBV nuclear proteins (EBNA2,
EBNA3A, EBNA3B, and EBNA3C) from LCL lysates (Fig 1, left panels). Although previous
work had suggested that EBNA2 and EBNA3C exist in distinct complexes [49], efforts to fur-
ther investigate whether EBNA3 proteins exist in distinct complexes have been hampered by
varying degrees of cross-reactivity of among available EBNA3A, EBNA3B, and EBNA3C anti-
bodies [43]. Using flag immunoprecipitation on EBNA3A-F-HA LCL lysates, we found that
EBNA3A and RBPJ were efficiently precipitated, but no EBNA1, EBNA2, EBNA3B, EBNA3C
or LMP1 was detectable (Fig 1, right panels). Immunoprecipitations using flag resin on
EBNA3B-F-HA or EBNA3C-F-HA LCL lysates produced similar results: RBPJ and the tagged
EBNA3 protein were readily detectable, but other EBV latency proteins were not. Control im-
munoprecipitations for HA (Fig 1, left panel) and flag (Fig 1, right panel) from wild-type LCLs,
did not precipitate any detectable RBPJ, EBNA2, or EBNA3 proteins. Thus, EBNA2, EBNA3A,
EBNA3B, and EBNA3C all associate with the same cell DNA binding protein, but appear to
form distinct RBPJ complexes in LCLs.
Fig 1. Characterization of EBNA3-F-HA LCLs, reveals that EBNA2, EBNA3A, EBNA3B, and EBNA3C
form distinct RBPJ complexes. Left panel: immunoprecipitation assay for RBPJ demonstrates it is in a
complex with EBNA2, EBNA3A, EBNA3B, and EBNA3C. HA immunoprecipitation serves as negative
control. Right panel: Selective immunoprecipitation of EBNA3A, EBNA3B, or EBNA3C complexes from
EBNA3-F-HA LCLs or WT LCL using Flag agarose. Precipitated complexes were resolved by SDS-PAGE
and probed for the indicated EBV latent proteins or RBPJ. For each LCL, one percent of the input lysate is
shown for comparison.
doi:10.1371/journal.ppat.1004822.g001
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EBNA3A and EBNA3B target the USP46/USP12 complexes in LCLs
In order to identify proteins that associate with EBNA3A, EBNA3B, or EBNA3C under physio-
logic conditions, we purified EBNA3 complexes by tandem affinity purification (TAP) from
LCLs expressing flag-HA tagged EBNA3A, EBNA3B or EBNA3C and from the wt LCL as a con-
trol. For each LCL, LC/MS/MS fingerprinting identified between 63–174 peptides of the epitope
tagged EBNA3 protein and 95–148 peptides corresponding to RBPJ (Table 1). For each
EBNA3-F-HA LCL, the purified protein complex contained peptides from the corresponding
epitope tagged EBNA3 protein and no peptides that mapped to the other untagged EBNA3 pro-
teins expressed in that LCL. No peptides from other EBV proteins, such as EBNA1, EBNA2, and
EBNALP, were detected in any complexes. Additionally, 14 peptides corresponding to CtBP1
were detected in the EBNA3A complex, but not in the EBNA3B, EBNA3C or control TAPs
(Table 1). We also detected 105, 99, and 3 total peptides corresponding to WDR48 in purified
EBNA3A, EBNA3B, and EBNA3C complexes, respectively. Importantly, in the EBNA3A and
EBNA3B complexes we also detected the knownWDR48 associated proteins WDR20 (28 and 4
peptides, respectively), USP46 (15 and 8 peptides, respectively), and USP12 (7 and 4 peptides,
respectively) (Table 1). Thus, analysis of tandem affinity purified EBNA3 complexes lends fur-
ther support to model that each EBNA3 protein, while highly associated with RBPJ, exists in a
distinct complex that does not contain other EBV nuclear proteins. Further, our results identify
the USP46 (and USP12) deubiquitinases and their associated chaperones WDR48 andWDR20
as members of the EBNA3A and EBNA3B protein complexes in LCLs. Because USP46 and
USP12 are highly homologous (~90% identity) and we could confirm a robust association with
USP46 byWestern blotting (discussed below), we chose to focus our subsequent attention on
the USP46/WDR48/WDR20 complex.
EBNA3C also interacts with the USP46 complex in LCLs
Given that the EBNA3 proteins share other protein binding partners (e.g., RBPJ and CtBP1)
and because we had previously identified WDR48 as a cell protein that interacts with flag-
EBNA3C aa365-545 [50], the small amounts of this protein detected in the EBNA3C was unex-
pected, particularly given the much larger amounts associated with EBNA3A and EBNA3B. We
considered the possibility that WDR48 became dissociated from EBNA3C during complex puri-
fication. Therefore EBNA3C complexes were rapidly immunoprecipitated from EBNA3C-F-HA
Table 1. Summary of peptides identified by mass spec of tandem affinity purifications (TAP).
Flag-HA tagged protein
none EBNA3A EBNA3B EBNA3C
EBNA3A 0 63 0 0
EBNA3B 0 0 146 0
EBNA3C 0 0 0 174
RBPJ 0 95 148 125
CtBP1 0 14 0 0
WDR48 0 105 99 3
WDR20 0 28 4 0
USP46 0 15 8 0
USP20 0 7 4 0
Total number of peptides detected for each EBNA3 protein and the host proteins RBPJ, CtBP1, WDR48, WDR20, USP46 and USP12 in puriﬁed
complexes is indicated. No peptides corresponding to any of these proteins were detected in the control TAP from wildtype LCLs.
doi:10.1371/journal.ppat.1004822.t001
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LCLs and blotted for associated proteins. Co-precipitated RBPJ was readily detected, as were
members of the USP46 complex, including USP46, WDR48, andWDR20 (Fig 2). Additionally
CtBP1, a known EBNA3C interacting protein [45] was detectable under these conditions even
though it was not detected in the TAP-MS experiments. Thus, EBNA3C also appears to target
the USP46 complex; however, this complex appears to be less stably associated with
EBNA3C-F-HA than it is with either EBNA3A-F-HA or EBNA3B-F-HA.
EBNA3-USP46 complexes are present in the nucleoplasm
Although originally described as an endosomal protein [51], WDR48 has subsequently been iso-
lated from other cellular compartments, including as a chaperone for USP1 in the nucleus as a
component of the Fanconi anemia DNA repair pathway [52]. Lehoux et al., found that USP12
and USP46 fused to red fluorescent protein were predominantly cytoplasmic in C33A cervical
carcinoma cells, but were recruited to the nucleus via an interaction with the HPV E1 helicase
Fig 2. EBNA3C associates with theWDR48/USP46 complex in EBNA3C-F-HA LCLs.
Immunoprecipitation assay using Flag agarose to retrieve protein complexes from EBNA3C-F-HA LCLs
(E3C-F-HA) is compared to flag immunoprecipiates from untagged wildtype (WT) LCLs. One percent of total
cell lysate (Input) or immunoprepicitated specimens using Flag agarose (Flag IP) were separated by SDS
PAGE and probed using antibodies to EBNA3C, RBPJ, CtBP1, WDR48, WDR20, USP46, or NF-kB p65.
doi:10.1371/journal.ppat.1004822.g002
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[53]. Because our TAP lysis procedure extracted both nuclear and cytoplasmic proteins (S2 Fig),
we wanted to ensure that the USP46/WDR48/WDR20 complex subcellular localization was
compatible with formation of a complex with EBNA3 proteins. To this end, we fractionated
LCLs into cytoplasm, membrane, nucleoplasm, chromatin, and cytoskeletal components (Fig 3).
Fraction purity was monitored by immunoblotting for control proteins of known localization:
alpha-tubulin (cytoplasm), BRG1 (chromatin associated), histone H2B (chromatin), and lamin B
(nuclear matrix/cytoskeleton). The EBNA3 proteins were predominantly found in the nucleo-
plasm with a small quantity stably associated with chromatin. Notably, a significant amount of
the WDR48, WDR20, and USP46 proteins were found in the nucleoplasm, with the balance
being extranuclear. To more directly assess whether EBV latent gene products might affect
USP46 localization, we compared fractions derived from EBV negative BL41 cells with fractions
derived BL41 cells super-infected with EBV (S3 Fig). Although USP46 was present in the nucleo-
plasm regardless of EBV status, we consistently observed an increase in nucleoplasmic USP46
Fig 3. Subcellular localization of USP46 complexes in LCLs.Wild type LCLs were extracted into five
subcellular fractions [cytoplasm (C), membrane (M), soluble nuclear (Nu), chromatin (Ch), cytoskeleton
(CS)], resolved by SDS-PAGE and probed for EBNA3 proteins, RBPJ, and components of the USP46
complex (USP46, WDR20, andWDR48). Fraction purity was assessed by probing for tubulin, BRG1, Histone
H2B, and LaminB.
doi:10.1371/journal.ppat.1004822.g003
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levels in EBV positive BL41 cells to varying degrees. We did not observe significant changes in
the levels of nucleoplasmic WDR48 orWDR20 in response to EBV infection; however, USP46
was increased in the membrane fraction upon EBV infection (S3 Fig), similar to that seen in
LCLs compared to uninfected BL41 cells. As expected, RBPJ was present in the nucleoplasm and,
to a much lesser extent, the chromatin fraction in LCLs and BL41 cells. We consistently observed
a portion of the cellular RBPJ in the cytoskeletal fraction of LCLs, but not in BL41 cells, regardless
of EBV infection. This may reflect RBPJ association with the nuclear cytoskeleton (matrix) as has
been previously reported [54]. In summary, these cell fractionation experiments are compatible
with EBNA3 proteins associating with a USP46 DUB complex that resides in the nucleoplasm of
B lymphocytes.
EBNA3 proteins interact most strongly with WDR48
To further study the association of the EBNA3 proteins with members of the USP46 complex,
Flag tagged EBNA3A, EBNA3B or EBNA3C was co-expressed with Xpress taggedWDR48,
WDR20, or USP46. Under these conditions, each of the EBNA3 proteins interacted with
WDR48, WDR20, and USP46. In each case, consistent with our LC/MS/MS data, the interaction
with WDR48 was the most robust (Fig 4A and 4B). We speculated that the EBNA3 proteins
may target the USP46 complex primarily via interactions with WDR48 and that, in our overex-
pression assay, only a small portion of theWDR20 or USP46 was complexed by endogenous
Fig 4. EBNA3 proteins preferentially bind theWDR48 subunit of the USP46 DUB complex. (A) Immunoprecipitation assay in 293T cells demonstrating
association of flag tagged EBNA3 proteins (F-E3A, F-E3B, and F-E3C) with WDR48 (left) andWDR20 (right). (B) Immunoprecipitation assay demonstrating
WDR48 cotransfection enhanced USP46 association with EBNA3s (right panel, compare lanes 3–5 with 8–10). Epitope tagged BNRF1 (F-HA-BNRF1), an
EBV protein of approximately the same size as the EBNA3 is included as an additional negative control. One percent (panel A) or two percent (panel B) of the
input are shown for comparison.
doi:10.1371/journal.ppat.1004822.g004
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WDR48. To test this, we also assessed the ability of each EBNA3 protein to co-precipitate
USP46 in the presence of additional WDR48 protein (Fig 4B). This markedly increased the re-
trieval of USP46, suggesting a central role for WDR48 in mediating interaction with the EBNA3
proteins. In order to test whether the EBNA3 proteins could recruit this DUB complex to RBPJ
complexes, we evaluated the ability of RBPJ andWDR48 to co-immunoprecipiate. In LCLs,
WDR48 could be weakly detected in RBPJ immunoprecipations; however in EBV negative BL41
cells, no binding above background could be discerned (Fig 5). These results are consistent with
a model in which EBNA3 proteins serve as adaptor proteins to recruit WDR48 to RPBJ in LCLs.
WDR48 binds to EBNA3A and EBNA3C domains important for LCL
proliferation
In order to map the EBNA3 residues that mediate interaction with WDR48, additional immu-
noprepicitation assays were conducted using EBNA3 deletion mutants. Each EBNA3 protein
was split into 3 approximately equal fragments, an N terminal region encompassing the RBPJ
binding motif, a central region, and a C-terminal domain. These 3 fragments were fused to
Flag and co-expressed with WDR48 in 293T cells. This revealed that EBNA3A aa524-944,
EBNA3B aa394-938, and EBNA3C aa365-545 interacted with WDR48 as well or better than
the full-length proteins (S4 Fig). We further mapped the EBNA3A and EBNA3C interactions
using internal deletion mutants that have been assessed for their ability to support LCL growth
[21,23] (Fig 6A and 6B). These data revealed that EBNA3A aa827-944 was critical for WDR48
interaction. In the case of EBNA3C, small deletions of aa447-500 or 501–544 disrupted interac-
tion with WDR48, as did mutation of the EBNA3C SUMO interaction motif (E3C509mSIM).
Importantly, EBNA3C mutants that were defective for WDR48 association correspond to mu-
tants that are intermediate for supporting LCL growth (Fig 6C). Thus, the EBNA3 domains re-
sponsible for association with WDR48, while not as critical as the RBPJ association domains
are important for EBNA3 mediated growth effects in LCLs.
Fig 5. WDR48 coimmunoprecipitates with RBPJ in EBV infected cells.Co-immunoprecipitation assays
comparing the association of RBPJ with WDR48 in LCLs with that observed in EBV negative BL41 cells. Cell
lysates were immunoprecipitated with polyclonal RBPJ sera, separated by SDS PAGE, and probed for
EBNA3A, EBNA3C,WDR48, and RBPJ (as indicated).
doi:10.1371/journal.ppat.1004822.g005
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A SUMO-like domain (SLD) within WDR48 mediates binding to EBNA3B
and EBNA3C, but not EBNA3A
In the Fanconi anemia DNA repair pathway, SUMO interaction motifs (SIMs) of the FANCI
protein associate with sumo-like domains (SLDs) within the WDR48 C-terminus [55]. Because
Fig 6. Identification of EBNA3A and EBNA3C domains that mediate WDR48 association.
Immunoprecipitation assays to mapWDR48 binding regions within EBNA3A (A) and EBNA3C (B). 293T cells
were co-transfected with Xpress taggedWDR48 and flag tagged full length EBNA3A, EBNA3C, or the
indicated EBNA3A or EBNA3C deletion mutants. Cell lysates were immunoprecipitated with Flag agarose,
separated by SDS PAGE, and probed for WDR48 (anti-Xpress) and EBNA3 proteins (anti-Flag). (C)
Comparison of WDR48 binding results (from B) with previously published RBPJ binding results and LCL
growth phenotype for each EBNA3Cmutant [21].
doi:10.1371/journal.ppat.1004822.g006
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EBNA3s proteins all contain SIMs [56], and our mapping data implicated the EBNA3C SIM in
WDR48 binding, we speculated that these SLDs might be important for EBNA3A, EBNA3B,
and EBNA3C interactions with WDR48. We first evaluated WDR48 aa1-634, a previously de-
scribed mutant (also called WDR48ΔSLD2) that is unable to associate with FANCI [55]. Flag-
EBNA3A was able to associate with this mutant comparable to wildtype WDR48 (Fig 7A). By
contrast, EBNA3B aa394-938, which associates strongly with full length WDR48, did not bind
to WDR48 aa1-634. The strong association of EBNA3C aa365-545 with full length WDR48
was almost completely lost with WDR48 aa1-634 (Fig 7A). To further define the EBNA3A
binding site, we constructed additional WDR48 truncation mutants: WDR48 aa1-535, which
removes the spacer region between SLD1 and SLD2 and WDR48 aa1-430, which is deleted for
both SLDs. Both WDR48 truncation mutants interacted with EBNA3A and WDR48 aa1-430
interacted as efficiently as full length WDR48 (Fig 7B). Thus, EBNA3B and EBNA3C require
the WDR48 SLD2 domain for binding, but EBNA3A can associate with the WDR48
N-terminus, independent of the SLDs.
CtBP1 andWDR48 bind distinct residues with EBNA3A aa827-944
Because EBNA3A aa827-944, which is essential for WDR48 binding, also contains two CtBP1
binding motifs [44], we sought to determine whether CtBP1 binding was separable from
WDR48 binding. Deletion of EBNA3A aa920-944 (EBNA3A 1–919) had no effect on CtBP1 or
RBPJ binding, but dramatically impaired WDR48 association in co-immunoprepicitation as-
says (Fig 8). Immunoprecipitations also confirmed that the previously described EBNA3A
CtBP1 binding mutant [44] retains the ability to bind to WDR48 with efficiency comparable to
wild type EBNA3A (Fig 8B). These data demonstrated that EBNA3A aa827-944 contain dis-
tinct binding sites for CtBP1 and WDR48.
An EBNA3Amutant defective for WDR48 association is impaired for
LCL growth maintenance
In order to assess whether WDR48 binding by EBNA3Amight be important for LCL growth, we
tested EBNA3A aa1-919, which binds CtBP1 but not WDR48 to binding, in EBNA3A-HT LCL
growth complementation. For these experiments EBNA3A-HT cells were transfected with
EBNA3A, EBNA3Amutant or control GFP expression plasmid, split, maintained in growth
media lacking 4HT and compared with control transfected cells grown in the presence of 4HT
(Fig 9A and S5 Fig). In the presence of 4HT (closed square) or transcomplemented wt EBNA3A
(closed diamond), LCL growth continued, whereas transcomplementation with EBNA3A CtBP1
binding mutant (open diamond) resulted in modestly impaired growth. By contrast, EBNA3A
mutants impaired for RBPJ orWDR48 association were unable to maintain LCL growth under
these conditions. Western blotting for p16 expression demonstrated that EBNA3Amutants de-
fective for supporting LCL growth, including the WDR48 binding mutant (EBNA3A aa1-919)
were impaired for suppression of p16 expression, compared to wild type EBNA3A (Fig 9B).
Purified EBNA3 complexes exhibit DUB activity
We assessed the ability of purified EBNA3 complexes to cleave ubiquitin from the 7-amino-
4-methlcoumarin (AMC) fluorophore (Fig 10A) in an effort to determine whether USP46/
USP12 deubiqutinase activity is activated or inhibited by association with EBNA3 proteins.
EBNA3 complexes, isolated by TAP from EBNA3A-F-HA LCL (closed circle), EBNA3B-F-HA
LCL (closed triangle), or EBNA3C-F-HA LCL (closed square) or control WT LCL (X), were in-
cubated with Ub-AMC reaction buffer and fluorescence intensities were measured by fluorom-
eter. For each EBNA3 complex, but not wt control, fluorescence intensity increased with time
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Fig 7. WDR48 SLD2mediates binding to EBNA3B and EBNA3C, but is not required for EBNA3A
binding. Immunoprecipitation assays were performed to assess effect of deleting theWDR48 SUMO-like
domains (SLDs) on EBNA3 binding. (A) 293T cells were co-transfected with vector control, Xpress tagged full
lengthWDR48 (FL) or a deletion mutant lacking the SLD2 domain (WDR48 1–634) and flag tagged EBNA3A
1–944 (F-E3A), EBNA3B 394–938 (F-E3B) or EBNA3C 365–545 (F-E3C). Cell lysates were
immunoprecipitated with Flag agarose, separated by SDS PAGE, and probed with WDR48 or Flag antibody.
(B) Immunoprecipitation assay to determine effect of deleting SLD1/2 onWDR48 binding to EBNA3A.
Assays were performed as describe above with co-transfection of EBNA3AWT and either full length WDR48
(FL), WDR48 1–535, or WDR48 1–430 (which lacks both SLD1 and SLD2).
doi:10.1371/journal.ppat.1004822.g007
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during the assay, consistent with DUB activity within each EBNA3 complex. Interestingly, the
amount of USP46 isolated from EBNA3C-F-HA LCLs was comparable to that seen in
EBNA3A or EBNA3B complexes (Fig 10B) further confirming the association of the USP46
DUB complex with EBNA3C in LCLs.
Inability to derive USP46 null LCLs using CRISPR/Cas9 gene editing
In order to assess the requirement for USP46 expression in LCLs, we attempted to knockout
USP46 expression using CRISPR/Cas9 gene editing. We cloned two guide RNA (gRNA) se-
quences into the pX330 vector, which allows simultaneous expression of the Cas9 nuclease and
a gRNA, and transferred this dual expression cassette into pCEP4 to allow hygromycin selec-
tion. Each construct was transfected into the 721 LCL and, as a control, 293T cells. We identified
multiple 293T cell populations in which no expression of USP46 could be detected (Fig 11). In
some cases, low level USP46 expression was detectable, which probably reflects the oligoclonal
nature of this experiment. By contrast, we observed no more than an ~50% reduction in USP46
levels in the 721 LCLs (Fig 11, top panels). To ensure that the CRISPR/Cas9 mediated gene edit-
ing had worked as intended we PCR amplified and sequenced the targeted region for each
USP46 gRNA from one cell population (c3 in each case). Sequencing results demonstrated that
in each population, at least one allele had undergone an in-frame deletion (S6 Fig), which would
Fig 8. Deletion of EBNA3A residues 920–944 disrupts WDR48 binding without affecting CtBP1
association. Co-immunoprecipitation assay to assess binding of EBNA3Amutants to WDR48 (A) and
CtBP1 (B). For these assays, flag tagged full length EBNA3A (1–944), an EBNA3A CtBP1 binding mutant
(mCtBP), an EBNA3Amutant lacking the C-terminal 25 residues (1–919), or vector control (pSG5) was co-
transfected with Xpress-WDR48 or HA-CtBP1. Lysates were immunoprecipitated with Flag agarose (A) or
HA agarose (B), separated by SDS PAGE, and probed with WDR48, RBPJ, flag, EBNA3A and
HA antibodies.
doi:10.1371/journal.ppat.1004822.g008
EBNA3 Proteins Target USP46/USP12 to Promote LCL Growth.
PLOS Pathogens | DOI:10.1371/journal.ppat.1004822 April 9, 2015 14 / 32
be predicted to abrogate further Cas9 cleavage, but not disrupt the USP46 open reading frame.
These sequencing results confirm that the USP46 gene was successfully edited in the 721 LCLs.
As a further test, we performed an independent replicate of our USP46 CRISPR/Cas9 knockout
in both cell lines (S7 Fig). In 293T cells, 22 of 39 clones were successfully knocked out for
USP46 expression, whereas we did not observe any USP46 knockout among 39 randomly select-
ed clones in the 721 LCL. This difference was highly statistically significant (p< 10–8) by a two-
tailed Fishers exact test. Our results suggest that the USP46 gene is dispensable in 293T cells, but
our inability to generate USP46 null LCLs using the same approach despite evidence for Cas9
mediated cleavage, implicates USP46 in LCL growth or survival.
Fig 9. EBNA3A1-919, which associates with CtBP1 but not WDR48, is impaired for LCL growth
maintenance. (A) Transcomplementation assay comparing growth of EBNA3A-HT cells transfected with
EBNA3AWT (closed diamond), EBNA3A 1–826 (open square), EBNA3AmCtBP1 (open diamond), EBNA3A
mRBPJ (open triangle), or EBNA3A 1–919 (X) in the absence of 4HT. EBNA3A-HT cells were also
transfected with a control GFP expression plasmid, split, and maintained in either the presence (closed
square) or absence (open circle) of 4HT. Cells were counted every 3 to 4 days, and diluted in fresh media to
maintain a concentration of 200,000 cells/mL. Based on dilution factors, total cell number was calculated and
is plotted on the Y-axis versus time. (B) Wild type EBNA3A, not mutant EBNA3A, suppresses p16 expression
level in trans-complemented cells. After 15 days of EBNA3AWT or EBNA3Amutant (1–826, mCtBP1,
mRBPJ, or 1–919) transfection, cells were harvested and protein expression was detected by
immunoblotting with p16 antibody and actin as an internal control. As a control experiment, GFP expression
plasmid was transfected into the cells and cultured with or without 4HT for 15 days. The ration of the p16 and
actin bands was quantified and is indicated in the bottom panel.
doi:10.1371/journal.ppat.1004822.g009
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Recruitment of WDR48 to the p14ARF promoter is EBNA3C dependent
To more directly assess whether EBNA3C interaction with the USP46/WDR48/WDR20, could
recruit the DUB complex to chromatin, we performed chromatin immunoprecipitation (ChIP)
assays for WDR48 in EBNA3C-HT LCLs and assayed for enrichment using qPCR [42]. We
first examined the EBNA3C binding site within the p14ARF promoter that was recently re-
ported to mediate recruitment of repressor complexes to this promoter. We observed an in-
crease in ChIP signal in the presence of 4HT over that seen with 4HT withdrawal (Fig 12). As
controls, we examined two additional sites located near the EIF2AK3 and PPIA genes which
are bound by cell transcription factors, but not by EBNA3C [42,57]. At each of these locations,
Fig 10. Purified EBNA3 complexes exhibit DUB activity. (A) Tandem affinity purification was performed
on wild type or EBNA3-F-HA expressing LCLs. Purified complexes from wild type (X), E3A-F-HA (closed
circle), E3B-F-HA (closed triangle), or E3C-F-HA (closed square) LCLs were assayed for DUB activity by
fluorometric assay using Ub-AMC as a substrate. (B) Western blot of purified EBNA3 complexes used in (A)
demonstrating selective precipitation of tagged EBNA3 protein complexes and co-purification of RBPJ and
USP46 proteins. Lysates derived from the equivalent of approximately 1.5x106 cells (input), 2.4x106 cells
(Flag elution), or 10x106 cells (HA elution) were loaded on each lane, separated by SDS PAGE, and probed
with EBNA3s, Flag, EBNA3A, and HA antibodies.
doi:10.1371/journal.ppat.1004822.g010
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we observed no enrichment for in the permissive (4HT+) condition relative to the EBNA3C in-
activation state (4HT-). Total levels of WDR48 and USP46 were unchanged upon 4HT with-
drawal (Fig 12B) thus increased signal in the WDR48 ChIP at the p14 was not attributable to
increased expression of the constituents of the USP46/WDR48/WDR20 complex by EBNA3C.
These results are consistent with an EBNA3C dependent recruitment or stabilization of
USP46/WDR48/WDR20 complex binding at the p14ARF promoter.
Discussion
In this manuscript, we report the first detailed characterization of EBNA3A, EBNA3B, and
EBNA3C complexes from LCLs. Despite an extensive literature on putative EBNA3 interacting
proteins, endogenous EBNA3 complexes have not previously been isolated and subjected to
LC/MS/MS analysis. The use of epitope tags permitted tandem affinity purification of these
Fig 11. Inability to derive USP46 null LCLs using CRISPR/ Cas9mediated gene editing. (A) Western
blot for USP46 in 721 LCLs cells transfected with a plasmid expressing either of two guide RNAs targeting
different USP46 exons (CRISPR 1 or CRISPR 2) and a hygromycin resistance gene. Prior to harvesting, cells
were subjected to hygromycin selection for one month (resulting in 6 clones for CRISPR 1 and 8 clones
CRISPR 2). Untransfected 721 cells are also shown (WT). As a loading control, lysates were probed for beta
actin (bottom panel). (B) Western blots of 293T cells that were transfected same CRISPR plasmids as in
panel A and also subjected to one month of hygromycin selection. Hygromycin resistance cells were
harvested and blotted for USP46 (specific band is indicated by arrowhead). Untransfected 293T cells are also
shown (WT).
doi:10.1371/journal.ppat.1004822.g011
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complexes and minimized the chances that observed differences in composition were attribut-
able to differences in the antibodies used. Our approach has additional advantages in that the
proteins were expressed at endogenous levels from their native promoters. Further, because
these recombinant EBV genomes were able to transform primary B lymphocytes into LCLs,
the epitope tags did not disrupt EBNA3 interactions essential for the transformation process.
Despite the large array of proteins reported to interact with each EBNA3, we identified only a
limited number of proteins specifically associated with the EBNA3s through the TAP proce-
dure. This limited overlap between binary protein-protein interaction screens and protein
complex composition is consistent with results from large scale protein interactome mapping
efforts [58]. It is a formal possibility that the purified EBNA3 complexes associated with these
cell proteins during the purification procedure. We view this as unlikely since it requires the
Fig 12. ChIP assay for WDR48 at the p14ARF promoter.Chromatin immunoprecipitation (ChIP) assays
were performed using antibodies for WDR48 (A) from EBNA3C-HT LCLs that were grown in the presence of
4HT (dark gray) or after 14 days of growth in the absence of 4HT (light gray). Amount of genomic DNA was
measured by real time PCR using primers specific to the EBNA3C binding site in the p14ARF promoters or
sites near the EIF2AK3 and PPIA genes which bind cell transcription factors but not EBNA3C. The bar graph
represents the amount of DNA precipitated relative to the amount of DNA in the corresponding input sample.
The experiment shown is representative of four independent experiments and error bars indicating standard
error of the mean within this experiment. Asterisk denotes that the difference in ChIP signal seen at the
p14ARF promoter is statistically significant (p = 0.01). (B) Western blot for USP46, WDR48, and tubulin levels
in whole cell lysates from EBNA3CHT LCLs grown in the presence of 4HT or after 14 days of growth in the
absence of 4HT.
doi:10.1371/journal.ppat.1004822.g012
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simultaneous assumption that the interaction is sufficiently strong to be maintained during the
TAP procedure, but does not occur endogenously despite these proteins being present in the
same subcellular fraction. One important caveat for our analysis is that the TAP procedure,
while highly specific, can be insensitive for weak interacting partners. Thus, the complexes de-
fined in our study may be most appropriately described as EBNA3 “core” complexes.
Each EBNA3 complex was found to include RBPJ, a transcription factor in the Notch signal-
ing pathway that is critical for EBNA3A and EBNA3C function in maintaining LCL growth. It
was previously known that EBNA2 and EBNA3C exist in separate RBPJ complexes [49]. Our re-
sults demonstrate that all four RBPJ-interacting EBNAs (2, 3A, 3B, and 3C) form distinct RBPJ
complexes. This has several important implications for the mechanisms by which EBNA3 pro-
teins can act to regulate transcription and their ability to modulate EBNA2 activation
[38,59,60,61]. First, despite binding to a distinct domain in the RBPJ N-terminus, EBNA3 pro-
teins are able to exclude EBNA2 which interacts with the RBPJ beta trefoil domain. Further, be-
cause EBNA3A and EBNA3Cmust each interact with RBPJ to maintain LCL growth via p16
promoter repression, it is likely that two different RBPJ molecules, and hence, binding sites are
required. Although we did not detect stable interactions among the EBNA3 complexes, it is con-
ceivable that interactions described by other investigators at these promoters are required for co-
operative gene regulation observed among EBNA3 proteins [62]. Indeed, it is tempting to
speculate that EBNA3 proteins exert their cooperative effects by exploiting paired RBPJ sites in
the human genome that are important for activation of specific genes by intracellular Notch [63].
Interactions with other transcription factors are also likely to be important for observed differ-
ences in EBNA3A, EBNA3B, and EBNA3C binding observed in ChIP-seq experiments [42,57].
Although we initially embarked on these experiments with the expectation of identifying
unique EBNA3A, EBNA3B, and EBNA3C interacting partners, we unexpectedly identified an-
other shared EBNA3 target: the USP46 and USP12 deubiqutinases (DUBs) and their chaper-
ones WDR48 andWDR20 [64,65]. Because we did not find peptides corresponding to other
EBNA proteins in these complexes, each EBNA3 protein appears to target RBPJ and the
USP46/USP12 DUB complexes independently. Each EBNA3 bound most strongly to WDR48,
and USP46 binding was enhanced by WDR48 co-transfection, consistent with WDR48 being
the primary mediator of EBNA3 binding to the USP46/USP12 DUB complexes. It is notable
that EBNA3B and EBNA3C target the WDR48 SLD2 domain, whereas EBNA3A interacts with
the WD repeats of WDR48. Thus, the EBNA3 proteins bind to WDR48 via their highly diver-
gent C-termini and do not all target the sameWDR48 subdomains. Whether these distinct
strategies for targeting the WDR48 protein are an accident of positive selection or account for
differences between EBNA3A and EBNA3C’s roles in LCL growth is not clear. These binding
site differences would allow for chromatin associated EBNA3A and EBNA3C to simultaneous-
ly bind (and potentially stabilize) a single WDR48 molecule, but we found no evidence for sta-
ble binding of both EBNA3A and EBNA3C in a single complex in our LC/MS/MS data.
Nevertheless, we find that USP46/WDR48/WDR20 is a component of endogenous EBNA3
complexes purified from LCLs and is bound by domains of EBNA3A and EBNA3C that are
important for p16 suppression and LCL growth. Taken together these findings suggest that
these DUB complexes are specifically targeted by EBNA3 proteins as part of the EBV lympho-
cyte transformation strategy.
The ubiquitin specific proteases USP12 and USP46 are close paralogs, that are 89% identical
over 357 residues and are both regulated by the WDR48 and WDR20 chaperones [64,66]. Al-
though the physiologic role of these enzymes is incompletely understood, they appear to exhib-
it partially overlapping substrate specificity [64]. The more distantly related USP1 is also
regulated by WDR48, but WDR20 is unique to USP12/USP46 complexes. We did not detect
any USP1 peptides in our complexes, suggesting that the even though the EBNA3 proteins
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interact strongly with WDR48, they are selective for USP12 and USP46 complexes, possibly
due to stabilizing interactions with WDR20 or the enzymes themselves. Although the PHLLP1
and PHLLP2 phosphatases have been reported to be components of the USP46 and USP12
complexes, they were not detectably associated with EBNA3 complexes, likely because these
phosphatases are predominantly membrane-associated [67,68,69,70]. Because regulation of the
steady state levels of the PHLLP phosphatases by USP46/USP12 is a critical regulatory step in
the Akt signaling pathway, EBNA3 proteins might influence PHLLP protein levels, and hence,
alter Akt signaling by binding this DUB complex. However, PHLLP1 was not detectable in our
LCLs and we found no evidence that PHLLP2 levels or Akt phosphorylation were effected by
EBNA3C inactivation (S8 Fig). Further, USP46 complexes were present in both the cytoplasm
and the nucleoplasm of LCLs and this distribution was also observed in EBV negative B cells.
Membrane associated USP46 and USP12 complexes have been implicated in regulating mem-
brane trafficking of receptors, including Notch1 and GLR1 [71,72]. Although it is possible that
EBNA3 proteins could affect this regulation, we do not favor this hypothesis as the levels of
membrane associated USP46 in LCLs are not reduced, but slightly higher than that observed in
EBV negative BL41 cells.
Our inability to derive USP46 null LCLs using CRIPSR/Cas9 gene editing is consistent with
USP46 playing an essential role in LCL growth or survival that it does not play in 293T cells.
Based on our observation that WDR48 plays a dominant role in mediating EBNA3 association
with the USP46 DUB complex and binds to EBNA3A and EBNA3C domains that are impor-
tant for regulation of p16, we suspect that the DUB complex interaction is important for tran-
scriptional effects of the EBNA3 proteins. We considered the possibility that this interaction
contributes to the long half-life of EBNA3 proteins; however the steady state levels of EBNA3A
and EBNA3CWDR48 binding mutants were not detectably different than wild type (Fig 6)
and there was no detectable difference in protein turnover in the presence of cyclohexamide
(S9 Fig). Instead, our results suggest that EBNA3 proteins act as adaptor molecules to target
USP46 complexes to promoters via interactions between RBPJ and other transcription factors.
This is supported by our observation that WDR48 is recruited the p14ARF promoter in an
EBNA3C dependent manner. Given the central role of ubiquitylation in transcriptional activa-
tion, we favor the hypothesis that the EBNA3 proteins recruit the DUB complex to remove ubi-
quitin molecules from other nuclear proteins. However, we are unaware of any unbiased
methods for determining the substrates of DUB complexes. Using a candidate substrate ap-
proach, we investigated the possibility that ubiquitylation of histone H2A (H2A-Ub) and H2B
(H2B-Ub) were targeted by these complexes as has been previously described in Xenopus [73].
However, we found global levels of H2A-Ub and H2B-Ub to be unaffected by the presence
EBNA3 proteins (S10 Fig). We did observe decreased H2A-Ub at the p16 promoter upon
EBNA3C-HT inactivation (S10 Fig) and no change in H2B-Ub levels. This is consistent with
decreased polycomb repression of p16 upon EBNA3C-HT inactivation, but not consistent with
recruitment of USP46 to chromatin playing a direct role in deubiquitylating histones at the
p16 promoter.
In summary, we find that the USP46/USP12 DUB complexes are a highly associated with
EBNA3 proteins in LCLs, interact with domains of EBNA3A and EBNA3C essential for LCL
growth, and that DUB activity is preserved in these complexes. The substrates upon which
these DUBs act upon in LCLs remain to be determined, despite our efforts to identify effects of
the EBNA3 proteins on several candidates. Although we have focused on transcriptional effects
of the EBNA3 proteins, it is likely that their ability to associate with the USP46/USP12 DUB
complexes explains other observed EBNA3 activities as well, most notably their effects on the
stability of cell proteins, including Mdm2, cyclin D, Gemin3, IRF4 or aurora kinase B
[27,30,31,74,75]. We believe that the identification of the USP46/USP12 DUBs as components
EBNA3 Proteins Target USP46/USP12 to Promote LCL Growth.
PLOS Pathogens | DOI:10.1371/journal.ppat.1004822 April 9, 2015 20 / 32
of the EBNA3 complexes in LCLs represents a significant advance in our understanding of the
multitude of roles played by EBNA3 proteins in B lymphocyte transformation.
Materials and Methods
Ethics statement
Lymphoblastoid cell lines (LCLs) described in this manuscript were derived by EBV transfor-
mation of peripheral blood B lymphocytes from de-identified donors, with written informed
consent, which is approved by Partners IRB based on Helsinki recommendations.
Cell lines
293T (obtained from Elliott Kieff, Harvard Medical School), a human cell line transformed by
adenovirus 5 and SV40 large T antigen [76], was cultured in Dulbecco’s modified Eagle’s
(Gibco) medium. The “wild-type” LCL, created with an unmodified EBV BACmid, was a gen-
erous gift from Fred Wang [47] and the 721 LCL was obtained from Bill Sugden [77]. LCLs
and P3HR1 ZHT cells [78], a type II EBV cell line, were cultured in RPMI 1640 (Gibco). Media
was supplemented with L-glutamine (Gibco), penicillin-streptomycin (Gibco) and 10–15%
FetalPlex (Gemini Bio-Products).
Plasmids
pBS-XS-EA contains the XbaI-SalI fragment from the EBV B95-8 genome containing the
EBNA3C region, in which the C-terminus of the EBNA3C ORF is mutated to create EcoRI and
AvrII sites (GATTCGATTAAGGGGATCCTAGG). pBS-EBNA3C-flag-HA-CAT was created
from pBS-XS-EA by inserting an oligo encoding the flag and HA epitopes (AATTGGATGAAT
TCGCGGCCGCTGGAGGAGACTACAAGGACGACGATGACAAGTCGGCCGCTGGAGG
ATACCCCTACGACGTGCCCGACTACGCCTAGGACGCGT annealed to CTAGACGCG
TGGATCCGCATCAGCCCGTGCAGCATCCCCATAGGAGGTCCGCGGCTGAACAGTA
GCAGCAGGAACATCAGAGGAGGTCGCCGGCGCTTAAGTAGG) and a PCR product
containing an FRT flanked CAT gene amplified from pKD3 using the primers (CACTGAA
TTCCTAGGTAGGTGTAGGCTGGAGCTGCTTCGAAG and TTGAATGAACGCGTCATA
TGAATATCCTCCTTAG). pSG5-EBNA3A-flag-HA-CAT and pSG5-EBNA3B-flag-HA-CAT
were created by cloning the NotI/MluI fragment from pBS-EBNA3C-flag-HA-CAT into
pSG5-EBNA3A and pSG5-EBNA3B which had been modified to create NotI/MluI sites allow-
ing the flag-HA tag to be fused in-frame with the EBNA3A or EBNA3B ORFs, respectively.
Plasmids for expression of EBNA3A and EBNA3C mutants have been previously described
[21,23]. pSG5-flag-EBNA3A 1–919 was constructed by PCR amplify of pSG5-Flag-EBNA3A
using primer pairs EBNA3A-C919 (ACAACAGCTGGCGGCCGCTACCTTCTAGTTTCAG
GGCCTGTGACATTTTGGCCAC) and EBNA3A-N543 (CTCAGGGAATGGCATACCCAT
TAC), digested with NotI/BssHII and recloned into pSG5-Flag-EBNA3A or pCEP-Flag-
EBNA3A. pSG5-Flag-E3A mCtBP1 was constructed same as previously described [44]. Flag-
tagged EBNA3B 1–938, 1–544, and 394–938 were constructed by PCR amplification from
pSG5-EBNA3B [23] using appropriate pairs of the following primers: E3B-N1 (TTGTACAAA
ACTGCAGGCATGAAGAAAGCGTGGCTCAG), E3B-C938 (AACTTTGTACGCGGCCG
CTTACTCATCGTTCGATGTTTCAGAAG), E3B-C544 (TCACTCTCTAGCGGCCGCTA
ACCGGTGAAGACACAAGGGCCTC), and E3B-N394 (CTGCCGTACACTGCAGCAGTA
TACGGCAGGCCCGCGGTG), and cloned into the PstI/NotI sites of pSG5-flag [79]. The ex-
pression construct for Xpress-tagged-WDR48 was a kind gift of Jae Jung [51]. WDR48 1–634
(ΔSLD2) was constructed using WDR48-N399 (GCAAAGTGGATTTTGAAGATG) and
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WDR48-C634 (AGTTCAATTGCGGCCGCCTACAACACAGCAATATCTTCTTC). Result-
ing PCR product was digested with HpaI/NotI and recloned into pcDNA4-WDR48. WDR48
1–535 (ΔSLD2) was constructed using WDR48 C535stop (TGTTTCATTAAGCGGCCGCTA
CGTTAACTAACCCCCGGAATCTCGGCAGAGCAGC) and WDR48-N295 (GCACCAGT
TCTCAAGATGGAGC). Resulting PCR product was digested with EcoRI/NotI and recloned
into pcDNA4-WDR48. Then WDR48 1–535 (ΔSLD2) was digested with HpaI and religated to
make WDR48 1–430 (ΔSLD1/2). Xpress tagged USP46 and WDR20 were constructed by am-
plifying the ORFs from ORFome 5.1 Entry clones (generous gifts of Marc Vidal) using the fol-
lowing primers: TGTACAAAAGGTACCTATGACTGTCCGAAACATCGCCTC + CTTTG
TACTCGAGCGGCCGCTATTCTCTTGACTGATAGAATAAAATATATC and TGTACAA
AAAGGTACCTATGGCGACGGAGGGAGGAGGGAAG + AACTTTGTACTCGAGCG
GCCGCTAAGGATTAAAACTTACCACTTTACCAG, respectively. Resulting PCR products
were KpnI/NotI digested and cloned into pCDNA4-HisMax-A (Invitrogen). All constructs
were verified by sequencing.
Recombinant EBV genomes
In frame C-terminal flag-HA tags were fused to the EBNA3A, EBNA3B, or EBNA3C ORFs as
follows: DNA fragments containing these fusions were either excised as an Xba/SalI fragment
(from pBS-E3C-flag-HA-CAT) or PCR amplified (from pSG5-E3A-flag-HA-CAT and
pSG5-E3B-flag-HA-CAT), using the E3A-F (TGACGTGGTCCAACATCAGC) and E3A-R
(GCGTATTATCAGTGGGTGGAATGGAGGGGGACACACTTCTACACCTTTGCCATAT
GAATATCCTCCTTAG) or the E3B-F (ACTCCCATGCAGCTGGCACTAAGGGC) and
E3B-R (CCCCGCAGTCTGTTGCCCCAGGGTTCATCCCAGTTCTTGTTACATGGGCG
CATATGAATATCCTCCTTAG) primers. Fragments were recombined into an EBV-BACmid
derived from the B95-8 genome using an inducible lambda red recombinase as previously de-
scribed [47]. Following transient expression of FLP recombinase, single colonies were plated
and screened for excision of the CAT gene.
LCL transformation using recombinant EBV genomes
Recombinant EBV-BACmids were transfected into P3HR1 ZHT cells, selected with puromycin
and induced for replication by addition of 4HT. Viral supernatant were collected and used to
transform peripheral blood B cells in to lymphoblastoid cells as previously described [23]. LCLs
were screened by PCR for recombinant genomes containing the flag-HA fused in frame to the
appropriate EBNA3 open reading frame and the absence of co-infecting P3HR1 genomes.
Antibodies
The following antibodies were used for Western blotting, immunoprecipitations and chromatin
immunoprepicitation: mouse monoclonal antibodies against HA.11 (16B12, Covance), Flag (M2
andM5, Sigma), Xpress (R910-25, Invitrogen), alpha-tubulin (B-5-1-2, Sigma), Glyceraldehyde-
3-Phosphate Dehydrogenase (GAPDH; 6C5, Millipore), Beta Actin (Sigma, A5441), BRG1
(PA5-17008, Thermo Scientific), LaminB (sc-6216, Santa Cruz), RBPJ (Hyb-T6709, Cosmo Bio
Co), CtBP1 (Q13363, Millipore), WDR48 (HPA038421, SIGMA or rabbit polyconal sera, a kind
gift of Alan D’Andrea), WDR20 (A301-657A, Bethyl Laboratories), USP46 (HPA007288,
Sigma), p16 (clone JC8, sc-56330, Santa Cruz Biotechnology), NF-kB p65 (8242, Cell Signalling),
EBNA1 (13-156-100, Advanced Biotechnologies), EBNA2 (PE2, [80]), EBNA3A (F115P, Exal-
pha Biologicals), EBNA3B (F120P, Exalpha Biologicals), EBNA3C (A10, [81]), LMP1 (S12,
[82]), EBNALP (4D3, a kind gift of Yasushi Kawaguchi [83]). histone H2A (#07–146, Millipore),
Ub-Histone H2A (#05–678, Millipore), histone H2B (07–371, Millipore), Ub-Histone H2B
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(#07–371, Millipore), PHLPP1 (A300-660A, Bethyl), PHLPP2 (A300-661A, Bethyl), Akt (#4691,
Cell signaling), p-Akt (#4060, Cell signaling), and GFP (sc-5384, Santa Cruz).
Tandem-affinity purification (TAP)
Approximately 6x108 cells from an LCL transformed with either a wild-type EBV BAC or a re-
combinant EBV BAC expressing either EBNA3A-F-HA, EBNA3B-F-HA, or EBNA3C-F-HA
were lysed in 10ml of TAP lysis buffer (1% (v/v) Igepal CA-630, 50mM TrisHCl [pH7.5],
140mM KCl, 10mM NaF, 1.5mM EDTA, and 5% glycerol) containing 10mM β-ME and
EDTA-free Complete protease inhibitor (Roche, Mannheim, Germany). Lysed cells were incu-
bated at 4°C for 30 minutes with constant rotation before being cleared by two rounds of cen-
trifugation at 8500rpm for 10 minutes and one spin at 10,000rpm for 20 minutes. Supernatants
were diluted as required to match total protein concentration as measured by Bradford assay
(BioRad). A 50μl aliquot was saved for Western blot analysis and the remaining supernatants
were incubated with 60μl of anti-Flag M2 agarose (Sigma) for 4 hours at 4°C with rotation. The
beads were washed extensively with TAP lysis buffer before being eluted with 60μl of 0.4mg/ml
Flag peptide (Sigma) in TAP buffer twice at 4°C for 30 minutes with shaking and once at 37°C
for 30 minutes with shaking. Elutions were passed through Bio-Spin columns (Bio-Rad) to re-
move entrained agarose beads and pooled. Agarose-conjugated HA beads, 25μl per sample,
(F7, Santa Cruz Biotechnology) were added to the pooled elutions and incubated overnight at
4°C with constant rotation. The beads were washed three times with TAP lysis buffer and elut-
ed with 30μl of 0.4mg/ml HA peptide (Covance) twice at 37°C for 30 minutes with shaking;
elutions were spun through Bio-Spin columns and pooled for LC/MS/MS analysis.
TAPmass-spectrometry analysis
Eluted samples (50μl) were mixed with 10μl of 4X LDS Loading Buffer (Invitrogen) separated
on a 10% Bis Tris NuPAGE MOPS gel (Invitrogen). Gels were fixed in destain solution (50%
methanol and 7.5% acetic acid), rehydrated, stained with Simply Blue Safestain (Invitrogen),
cut horizontally into one slice per sample, and destained until transparent. Gel slices were re-
duced with DTT, alklyated with iodoacetamide, and then rinsed with three alternating washes
of 50 mM ammonium bicarbonate and acetonitrile. Each slice was then digested with trypsin
by resuspending in 50mM ammonium bicarbonate/10% acetonitrile/5.5g/mL trypsin and incu-
bating at 37°C for 24 hours. Peptides were extracted with one rinse of 50mM ammonium bicar-
bonate/10% acetonitrile followed by one rinse of 50% acetonitrile/0.1% formic acid,
lyophilized, then rehydration in 20μL 96% water, 4% methanol, and 0.2% formic acid.
Digested samples were loaded into 96-well plates for mass spectrometry analysis on a
LTQ-Velos Orbitrap XL (Thermo Fisher Scientific) instrument. For each run, 10μL of each re-
constituted sample was injected onto an Easy nLC system configured with a 10cmx100um trap
column and a 25cm x 100um ID resolving column (Thermo Scientific). Buffer A was 96%
water, 4% methanol, 0.2% formic acid and Buffer B was 10% water, 90% acetonitrile, and 0.2%
formic acid. Samples were loaded at 5μL a minute for 9 minutes, and a gradient from 0–60% B
at 375nl/minute was run over 70 minutes, for a total run time of 115minutes (including regen-
eration, and sample loading). Velos-Orbitrap (Thermo Scientific) was run in a standard data
dependent Top 10 configuration at 60K resolution for a full scan, with monoisotopic precursor
selection enabled, and +1, and unassigned charge state rejected. MS2 fragmentation and analy-
sis was performed in the ion trap using CID fragmentation.
Peptides were identified using SEQUEST (Thermo Fisher Scientific) through Protein Dis-
coverer, version 1.2. MS/MS data were searched using 10ppm mass accuracy on precursor m/z
and a 0.5Da window on fragment ions. Fully enzymatic tryptic searches with up to three missed
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cleavage sites were allowed. Oxidized methionines were searched as a variable modification
and alkylated cysteines were searched as a fixed modification. Sequential database searches
were performed using the NCBI RefSeqHuman FASTA database. Peptides for each charge
state were filtered to a false discovery rate (FDR) of 1%.
Subcellular fractionation
Subcellular fractionation was performed using the subcellular protein fractionation kit (Thermo
Scientific Pierce) according to the manufacturer’s instructions. For each fraction, an amount cor-
responding to that derived from 400,000 cells was resolved by SDS-PAGE and probed for
EBNA3 proteins, RBPJ, and components of the USP46 complex (USP46, WDR20, andWDR48).
Fraction purity was assessed by probing for tubulin, BRG1, Histone H2B, and LaminB.
TAP Ub-AMC assay
In vitro deubiquitination assays using TAP purified EBNA3s complex and Ub-AMC (U-550,
Boston Biochem) as a substrate were performed in 100uL of reaction buffer (20 mM
HEPES-KOH at pH 7.8, 20 mM NaCl, 0.1 mg/mL BSA, 0.5 mM EDTA, 20mM beta-
mercaptoethanol). Fluorescence signal was monitored in VICTOR X5 multilabel plate
reader (Perkin Elmer).
Immunoprecipitation
Transfected 293T cells which were harvested from 10cm tissue culture dishes or ten million of
LCLs were lysed into IP lysis buffer (1% (v/v) Igepal CA-630, 40mM TrisHCl [pH7.5], 150mM
NaCl, and 10mMMgCl2) supplemented with fresh 0.015mg/mL aprotinin (Sigma), 0.5mM
PMSF, and 1ug/ml Leupeptin. Lysates were incubated at 4°C for 30 minutes with rotation and
cleared by centrifugation at 10,000x g for 15 minutes. Supernatants were pre-cleared by rotat-
ing with Sepharose (Sigma) for 1 hour at 4°C and then incubated with anti-Flag M2 agarose,
anti-HA magnetic beads (cloneTANA2, MBL), or protein A/G for 2 hours at 4°C with rotation.
The beads were washed extensively with IP lysis buffer and either eluted with 0.4 mg/ml Flag
peptide or 0.4mg/ml HA peptide in IP lysis buffer at 37°C for 30 minutes with shaking or resus-
pend into SDS sampling buffer. The proteins were analyzed by Western blotting.
Western blot analysis
Total-cell lysates or immunoprecipitated proteins were separated by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membrane, and probed
with appropriate antibodies. After extensive washing, horseradish peroxidase conjugated sec-
ondary antibodies (Jackson Immuno Research) were applied. After incubation for 1–2 hours
the membrane was washed again, and developed with chemiluminescence reagent (Perkin
Elmer). Western blots were exposed on film and visualized on a KODAK Image Station 4000R
(Kodak Molecular Imaging Systems).
Complementation assay
Five million of EBNA3AHT-infected LCLs [23] were transfected with 2ug of oriP plasmid
DNA expressing EBNA3A, EBNA3A mutant or control plasmid. LCLs were harvested during
log-phase growth, washed with complete medium, resuspended in 100ul of buffer V with DNA
in a cuvette, transfected using program X-001 of Amaxa Nucleofector (Lonza), and cultured
for 3 days in LCL-conditioned medium with 4-hydroxy-tamoxifen (4HT). Cells were then
washed with PBS twice, and cultured in complete medium with or without 4HT. Every 4 to 7
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days, cell numbers were counted, cultures were split, and the total numbers of viable cells rela-
tive to those of the initial culture were calculated.
CRISPR/ Cas9 plasmids and knockout USP46 gene
Cas9 mediated editing of the USP46 gene was accomplished by cloning either of two targeting
20mers for the gRNA (CRISPR-1 in exon3: AAACTTGCTGACGTGCCTGG and CRISPR 2 in
exon4: TATTGCGGACATCCTTCAGG) [84,85] into the pX330 plasmid [86]. The Cas9 ex-
pression cassette and gRNA were excised from pX330 by PciI/ NotI digestion and cloned into
pCEP4 with a modified polylinker sequence, which allowed for hygromycin selection via an
self-maintaining episomal plasmid.
Five million of EBV transformed LCLs were harvested during log-phase growth, resuspended
in 100ul of buffer Ingenio with pCEP-CRISPR-USP46 plasmid, transfected using program U-
001 of Amaxa Nucleofector, and cultured for 2 days in RPMI1640 complete medium. 20,000
cells were plated on 96 well culture plate using RPMI1640 complete medium with 300ug/ml
hygromycin for one month. For 293T cells, one million cells were transfected with pCEP-CRIS-
PR-USP46 plasmid using Effectene, recovered for 48 hours, and then subjected to hygromycin
selection. Hygromycin resistance cells were harvested and screened with DNA PCR using primer
pairs (CRISPR-1 F: GGTGAGCTGGACTCCAATACAGGG and R: GCCAGCTCTTCCTTTTG
AGGAGAT or CRISPR-2 F: GGAGGCAGAGGTTGCAGTGAACTG and R: GCAATCACAT
GCAACATAGCGTAC) andWestern blotting analysis. These primers were also used for Sanger
sequencing of PCR products. USP46Western blot signals were quantified and normalized to tu-
bulin signal. For statistical analysis any cell line exhibiting>25% normalized USP46 signal was
considered positive.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as described previously [87]. Briefly, 2x106 cells per ChIP were
fixed in 1% (wt/vol) formaldehyde and sonicated using cup horns sonication system (Qsonica).
After extract clearing by centrifugation, supernatants were diluted and incubated with protein
G agarose with salmon sperm DNA (Millipore) for 1 h with rotation at 4°C. Protein G agarose
was pelleted and supernatants were used in ChIP experiments. One or two micrograms of anti-
body were added per 2x106 cells, followed by incubation overnight at 4°C with rotation. Puri-
fied DNA was quantified using gene specific primers and iTaq universal SYBR green supermix
(Bio-Rad) using a CFX96 touch real-time PCR detection system (Bio-Rad). Primers used for
these experiments were as follows: p16 TSS [32], p14ARF [42], EIF2AK3 (F: CTTCCGGACG
CAATTACCAATGAG and R: GTAGGAAAGGTATTCCGGGAACTG) or PPIA [57].
Supporting Information
S1 Fig. Characterization of LCLs transformed by recombinant EBV genomes expressing
epitope-tagged EBNA3A, EBNA3B, or EBNA3C.Western blot demonstrating EBV latent
protein expression in wild-type (WT), EBNA3A-Flag-HA (E3A-F-HA), EBNA3B-Flag-HA
(E3B-F-HA), or EBNA3C-Flag-HA (E3C-F-HA) LCL is shown. Total cell lysates were separat-
ed by SDS PAGE and probed with antibodies for EBV latent proteins (EBNA-1, -2, -3A, -3B,
-3C, -LP, or LMP1), RBPJ, or GAPDH.
(TIF)
S2 Fig. Efficiency of TAP lysis procedure for extracting EBNA3s and DUB complex compo-
nents. LCLs were lysed in TAP lysis buffer as detailed in the methods section and the residual
pellet resuspended as a separate fraction in 1x SDS sample buffer. Total cell lysates, TAP buffer
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soluble (Lysate) or insoluble (Pellet) fractions were separated by SDS PAGE and probed for
EBNA3s, RBPJ, WDR48, WDR20, or USP46 using appropriate antibodies. Fractions were also
assessed for control proteins: tubulin (cytoplasm), BRG1 (chromatin associated), Histone H2B
(chromatin), and LaminB (cytoskeleton).
(TIF)
S3 Fig. USP46 distribution in EBV positive and negative cells. Subcelluar fractionation was
performed as for Fig 3 in LCLs, EBV negative BL41 cells and BL41 cells exogenously infected
with EBV. Subcellular fractions were blotted with the indicated antibodies. Results of two inde-
pendent experiments are shown.
(TIF)
S4 Fig. Coarse mapping of WDR48 binding domains of EBNA3A, EBNA3B, and EBNA3C.
Immunoprecipitation assay to identify WDR48 binding regions with EBNA3A (panel A),
EBNA3B (panel B), or EBNA3C (panel C). 293T cells were co-transfected with Xpress tagged
WDR48 and flag tagged EBNA3A, EBNA3B, EBNA3C, or the indicated deletion mutants. Ly-
sates were immunoprecipitated with Flag agarose, separated by SDS PAGE, and probed with
for Xpress (WDR48) and Flag (EBNA3) antibody as indicated.
(TIF)
S5 Fig. EBNA3A1-919, which associates with CtBP1 but not WDR48, is impaired for LCL
growth maintenance. Complementation assays were performed as described in Fig 9 in
EBNA3A-HT LCLs. Results of two independent experiments are shown. Growth curves for
cells transfected with the following EBNA3A expression plasmids and maintained in the ab-
sence of 4HT are shown: EBNA3AWT (closed diamond), EBNA3A 1–826 (open square),
EBNA3A mCtBP1 (open diamond), EBNA3A mRBPJ (open triangle), or EBNA3A 1–919 (X)
in the absence of 4HT. EBNA3A-HT cells were also transfected with a control GFP expression
plasmid, split, and maintained in either the presence (closed square) or absence (open circle) of
4HT.
(TIF)
S6 Fig. Sequence analysis of the USP46 knockout LCLs. To determine CRISPR-Cas9 editing
of the USP46 gene was sucessful in the 721 LCL, we sequenced PCR products from primers
flanking the targeted 20mer from one clone for each gRNA. Shown the resultant sequences
traces corresponding to 721/ UPS46 CRIPSR1 cln3 and 721/ UPS46 CRIPSR2 cln3 and
their interpretations.
(TIF)
S7 Fig. Inability to derive USP46 null LCLs using CRISPR/ Cas9 mediated gene editing.
(A) Western blot for USP46 in 721 LCLs cells transfected with a plasmid expressing either of
two guide RNAs targeting different USP46 exons as was done in Fig 11. Untransfected 721
cells are also shown (WT). As a loading control, lysates were probed for tubulin (bottom pan-
els). (B) Western blots of untrasnfected 293T cells (WT) or 293T cells that were transfected
same CRISPR plasmids and also subjected to one month of hygromycin selection. Cell lines in
which USP46 expression was successfully knocked-out are circled.
(TIF)
S8 Fig. Effect of EBNA3C inactivation on the PHLPP/Akt pathways. EBNA3C-HT LCLs
were grown in the presence of 4HT or harvested at the indicated times after 4HT withdrawal.
Levels of PHLPP1, PHLPP2, Akt and phoso-Akt were determined by immunoblotting
as indicated.
(TIF)
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S9 Fig. The stability of mutants of EBNA3A and EBNA3C that do not bind USP46 is unal-
tered. Cells were treated with cycloheximide to determine whether USP46 binding alters
EBNA3A or EBNA3C protein stability. EBNA3A wild type, EBNA3A mCtBP1, EBNA3A
1–919 (ΔWDR48), EBNA3C wild type, or EBNA3C 509mSIM was contranfected with destabi-
lized GFP plasmid into 293T cells. After 24 hours cells were treated with 10ug/ml of CHX (0h)
and harvested indicated time. Lysates were separated by SDS PAGE and probed with EBNA3A
or EBNA3C, GFP, and Tubulin antibodies.
(TIF)
S10 Fig. Effect of EBNA3C inactivation on histone ubiquitylation at p16 promoter.
(A) Western blots to detect levels of global H2A and H2B ubiquityaltion in 293T cells trans-
fected with USP46 with or without cotransfected EBNA3A or EBNA3C. (B) Immunoblots
demonstrating the effect of inactivation of EBNA3C by 4HT withdrawal in E3C-HT LCLs on
global levels of H2A and H2B ubiquitylation. (C) ChIP-assay examining the effect of EBNA3C
inactivation in E3C-HT cells on H2A-Ub and U2B-Ub levels at the p16 promoter. This experi-
ment is typical of three independent experiments.
(TIF)
S1 Table. EBNA3A LC/MS/MS data. Result file from SEQUEST analysis of tandem affinity
purified EBNA3A complexes exported into excel file format.
(XLS)
S2 Table. EBNA3B LC/MS/MS data. Result file from SEQUEST analysis of tandem affinity
purified EBNA3B complexes exported into excel file format.
(XLS)
S3 Table. EBNA3C LC/MS/MS data. Result file from SEQUEST analysis of tandem affinity
purified EBNA3C complexes exported into excel file format.
(XLS)
S4 Table. Control wtLCL LC/MS/MS data. Result file from SEQUEST analysis of tandem af-
finity purification from control (wildtype) LCL exported into excel file format.
(XLS)
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